A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP
Study sponsor: Zai Lab (Hong Kong), Ltd.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-01-01Estimated
Enrollment · participants100Estimated
Source updated2024-06-14Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.